Provided by Tiger Trade Technology Pte. Ltd.

INNOVENT BIO

103.800
-3.700-3.44%
Volume:17.01M
Turnover:1.76B
Market Cap:181.03B
PE:189.37
High:106.400
Open:104.300
Low:101.500
Close:107.500
52wk High:112.700
52wk Low:69.550
Shares:1.74B
HK Float Shares:1.74B
Volume Ratio:0.95
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.548
ROE:7.01%
ROA:2.10%
PB:7.48
PE(LYR):189.37
PS:9.88

Loading ...

Movement Alert|INNOVENT BIO Rises 3.78% in Regular Trading, Strong H1 Performance and New Retail Channel Expansion Fuel Optimism

Market Focus
·
Aug 17

Spero Q2 FY26 Net Loss Widens to $9.6 Million; Revenue Posts no Revenue

Reuters
·
Aug 13

Innovent Biologics Schedules 25 Aug 2026 Board Meeting to Approve 1H26 Results

Bulletin Express
·
Aug 10

Innovent Biologics Schedules Board Meeting to Review Interim Results

Reuters
·
Aug 10

Innovent Biologics Slashes Prices on Weight-Loss Drug as Growth Concerns Mount

Deep News
·
Aug 10

Movement Alert|INNOVENT BIO Rises 3.06% in Regular Trading, H1 Revenue Significantly Beats Expectations as Multiple Banks Raise Target Prices

Market Focus
·
Aug 10

Innovent Biologics Signs Exclusive Deal with Daiichi Sankyo to Commercialize Vanflyta in China

Reuters
·
Aug 10

Biotech ETF Gains Over 5% as Leading Innovators Report Strong Earnings and Global Supply Chain Remains Robust

Stock News
·
Aug 07

Movement Alert|INNOVENT BIO Rises 3.02% in Regular Trading, Multiple Banks Raise Target Prices on Strong Revenue Beat and Pipeline Progress

Market Focus
·
Aug 07

Goldman Sachs Lifts INNOVENT BIO Target to HKD 111.68 on Strong H1 Product Revenue Growth

Stock News
·
Aug 06

Innovent Announces First Patient Dosed in Pivotal Registrational Study of Ibi363/Tak-928 (Pd-1/Il-2Α-Biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China

THOMSON REUTERS
·
Aug 06

Citigroup Maintains Bullish Stance on INNOVENT BIO with HK$115 Price Target

Deep News
·
Aug 05

CLSA: INNOVENT BIO (01801) First-Half Product Revenue Significantly Exceeds Expectations, Serving as a Positive Catalyst for Stock Price

Stock News
·
Aug 05

Innovent Biologics' Product Revenue Surges 60% in Q2

MT Newswires Live
·
Aug 05

Innovent Biologics Jumps Most in 3 Weeks on Robust Product Revenue Growth

Reuters
·
Aug 05

INNOVENT BIO shares open over 2% higher as first-half product revenue exceeds RMB 8.2 billion, marking a 55% surge

Stock News
·
Aug 05

Movement Alert|INNOVENT BIO Rises 5.77% in Regular Trading, H1 Product Revenue Exceeds RMB 8.2 Billion with 55%+ YoY Growth

Market Focus
·
Aug 05

Hong Kong Listed Companies' News Digest: Innovent Bio's First-Half Product Revenue Exceeds RMB 8.2 Billion, Up Over 55% Year-on-Year

Stock News
·
Aug 05

Innovent Biologics Says First Half 2026 Product Revenue Exceeds Rmb8.2 Billion

Reuters
·
Aug 05

Innovent reports H1 2026 product revenue surpassing RMB 8.20 billion, up more than 55%; Q2 alone tops RMB 4.30 billion with 60% growth

Bulletin Express
·
Aug 05